Cargando…
Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease
Background: Adropin, a peptide translated from the Energy Homeostasis Associated gene (ENHO), was mainly expressed in the liver and was a regulator in metabolic and energy homeostasis. This study aims to investigate the correlation between adropin and histological characteristics of the liver, and t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339918/ https://www.ncbi.nlm.nih.gov/pubmed/34366886 http://dx.doi.org/10.3389/fphys.2021.696163 |
_version_ | 1783733697393983488 |
---|---|
author | Li, Na Xie, Guomin Zhou, Biao Qu, Aijuan Meng, Hua Liu, Jia Wang, Guang |
author_facet | Li, Na Xie, Guomin Zhou, Biao Qu, Aijuan Meng, Hua Liu, Jia Wang, Guang |
author_sort | Li, Na |
collection | PubMed |
description | Background: Adropin, a peptide translated from the Energy Homeostasis Associated gene (ENHO), was mainly expressed in the liver and was a regulator in metabolic and energy homeostasis. This study aims to investigate the correlation between adropin and histological characteristics of the liver, and the clinical relevance of adropin in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). Methods: A total of 62 subjects, including 32 healthy controls and 30 MAFLD patients, were enrolled in this case-control study. The MAFLD patients were further divided into two subgroups, including NGT-M group and T2DM-M group. Serum adropin levels, metabolic parameters and intrahepatic lipids, the liver ENHO mRNA expressions and histological characteristics were investigated. Results: MAFLD patients showed significantly lower circulating adropin compared with healthy controls (2.02 ± 2.92 vs. 5.52 ± 0.65 ng/mL, P < 0.0001). Subgroup analysis exhibited dramatically declined serum adropin levels in T2DM-M patients compared with NGT-M group (0.51 ± 0.73 vs. 4.00 ± 3.52 ng/mL, P < 0.001). H&E and Oil Red O staining show exacerbated steatohepatitis in T2DM-M patients in contrast with NGT-M group. Furthermore, serum adropin concentrations were negatively correlated with intrahepatic triglyceride (TG), total cholesterol (TC), and NAFLD activity score (NAS) (TG: r = −0.495; TC: r = −0.392; NAS: r = −0.451; all P < 0.05). Conclusions: MAFLD patients showed significantly lower adropin levels than the healthy controls, especially in T2DM patients. Adropin maybe a potential biomarker for predicting the development of MAFLD, especially in T2DM individuals. |
format | Online Article Text |
id | pubmed-8339918 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83399182021-08-06 Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease Li, Na Xie, Guomin Zhou, Biao Qu, Aijuan Meng, Hua Liu, Jia Wang, Guang Front Physiol Physiology Background: Adropin, a peptide translated from the Energy Homeostasis Associated gene (ENHO), was mainly expressed in the liver and was a regulator in metabolic and energy homeostasis. This study aims to investigate the correlation between adropin and histological characteristics of the liver, and the clinical relevance of adropin in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). Methods: A total of 62 subjects, including 32 healthy controls and 30 MAFLD patients, were enrolled in this case-control study. The MAFLD patients were further divided into two subgroups, including NGT-M group and T2DM-M group. Serum adropin levels, metabolic parameters and intrahepatic lipids, the liver ENHO mRNA expressions and histological characteristics were investigated. Results: MAFLD patients showed significantly lower circulating adropin compared with healthy controls (2.02 ± 2.92 vs. 5.52 ± 0.65 ng/mL, P < 0.0001). Subgroup analysis exhibited dramatically declined serum adropin levels in T2DM-M patients compared with NGT-M group (0.51 ± 0.73 vs. 4.00 ± 3.52 ng/mL, P < 0.001). H&E and Oil Red O staining show exacerbated steatohepatitis in T2DM-M patients in contrast with NGT-M group. Furthermore, serum adropin concentrations were negatively correlated with intrahepatic triglyceride (TG), total cholesterol (TC), and NAFLD activity score (NAS) (TG: r = −0.495; TC: r = −0.392; NAS: r = −0.451; all P < 0.05). Conclusions: MAFLD patients showed significantly lower adropin levels than the healthy controls, especially in T2DM patients. Adropin maybe a potential biomarker for predicting the development of MAFLD, especially in T2DM individuals. Frontiers Media S.A. 2021-07-22 /pmc/articles/PMC8339918/ /pubmed/34366886 http://dx.doi.org/10.3389/fphys.2021.696163 Text en Copyright © 2021 Li, Xie, Zhou, Qu, Meng, Liu and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Li, Na Xie, Guomin Zhou, Biao Qu, Aijuan Meng, Hua Liu, Jia Wang, Guang Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease |
title | Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease |
title_full | Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease |
title_fullStr | Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease |
title_full_unstemmed | Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease |
title_short | Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease |
title_sort | serum adropin as a potential biomarker for predicting the development of type 2 diabetes mellitus in individuals with metabolic dysfunction-associated fatty liver disease |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339918/ https://www.ncbi.nlm.nih.gov/pubmed/34366886 http://dx.doi.org/10.3389/fphys.2021.696163 |
work_keys_str_mv | AT lina serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease AT xieguomin serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease AT zhoubiao serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease AT quaijuan serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease AT menghua serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease AT liujia serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease AT wangguang serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease |